Analyst Ratings for Summit Therapeutics plc (SMMT)
SMMT Rating Summary
SMMT Price Target Summary
- Highest: $42.00 (Jefferies)
- Lowest: $12.00 (Leerink Partners)
- Average: $30.91
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$30.91 (+104.6%)
* Over Last 12-Mos
Rating Score: 7.4 / 10
Percentile Rank: 78%
Avg. $ Target:
$30.91 (+104.6%)
* Over Last 12-Mos
Rating Score: 7.4 / 10
Percentile Rank: 78%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 12/17/2025 | Barclays | Etzer Darout | Upgrade | Equalweight (Underweight) |
18.00 (16.00) |
17.38 (15.11) |
-13.06% | Details |
| 11/18/2025 | Wolfe Research | Kalpit Patel | New Coverage | Peerperform (N/A) |
N/A (N/A) |
18.03 (15.11) |
-16.2% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
